CHI3L1 and metabolic dysfunction-associated steatohepatitis: The NIS4 model was further optimized in 2023 as the NIS2 + TM (including miR-34a-5p and YKL-40), providing a more effective non-invasive method in which to rule out high-risk NASH for patients at risk (77).